No, GLP-1 receptor agonists are not licensed by the MHRA or EMA for treating or preventing Alzheimer's disease
With the evolution of oral GLP-1 therapies, the healthcare landscape is shifting in ways that present both opportunities and responsibilities
This is partly because GLP-1s slow the digestive tract, reducing hydration
How do oral BPC supplements support wellness
With patented Velox, high-dose L-citrulline and L-arginine for an intense pump, beta-alanine to delay fatigue, and an anti-caffeine crash complex with L-theanine, this formula gives you everything you need for peak performance
The Nat Geo article is not peer reviewed itself, but the studies mentioned within it are, except where it specifically identifies them as preprints